Literature DB >> 34283079

Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis.

Inja Ilic1, Anton Faron2, Muriel Heimann1, Anna-Laura Potthoff1, Niklas Schäfer3, Christian Bode4, Valeri Borger1, Lars Eichhorn4, Frank A Giordano5, Erdem Güresir1, Andreas H Jacobs6, Yon-Dschun Ko7, Jennifer Landsberg8, Felix Lehmann4, Alexander Radbruch9, Ulrich Herrlinger3, Hartmut Vatter1, Patrick Schuss1, Matthias Schneider1.   

Abstract

Neurosurgical resection represents an important therapeutic pillar in patients with brain metastasis (BM). Such extended treatment modalities require preoperative assessment of patients' physical status to estimate individual treatment success. The aim of the present study was to analyze the predictive value of frailty and sarcopenia as assessment tools for physiological integrity in patients with non-small cell lung cancer (NSCLC) who had undergone surgery for BM. Between 2013 and 2018, 141 patients were surgically treated for BM from NSCLC at the authors' institution. The preoperative physical condition was assessed by the temporal muscle thickness (TMT) as a surrogate parameter for sarcopenia and the modified frailty index (mFI). For the ≥65 aged group, median overall survival (mOS) significantly differed between patients classified as 'frail' (mFI ≥ 0.27) and 'least and moderately frail' (mFI < 0.27) (15 months versus 11 months (p = 0.02)). Sarcopenia revealed significant differences in mOS for the <65 aged group (10 versus 18 months for patients with and without sarcopenia (p = 0.036)). The present study confirms a predictive value of preoperative frailty and sarcopenia with respect to OS in patients with NSCLC and surgically treated BM. A combined assessment of mFI and TMT allows the prediction of OS across all age groups.

Entities:  

Keywords:  brain metastases; frailty; non-small cell lung cancer; outcome; overall survival; sarcopenia

Year:  2021        PMID: 34283079     DOI: 10.3390/cancers13133353

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  5 in total

1.  Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis.

Authors:  Motaz Hamed; Niklas Schäfer; Christian Bode; Valeri Borger; Anna-Laura Potthoff; Lars Eichhorn; Frank A Giordano; Erdem Güresir; Muriel Heimann; Yon-Dschun Ko; Jennifer Landsberg; Felix Lehmann; Alexander Radbruch; Elisa Scharnböck; Christina Schaub; Katjana S Schwab; Johannes Weller; Ulrich Herrlinger; Hartmut Vatter; Patrick Schuss; Matthias Schneider
Journal:  Front Oncol       Date:  2021-09-14       Impact factor: 6.244

2.  Association between Temporal Muscle Thickness and Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis.

Authors:  Young Il Kim; Ja Young Shin; Seung Ho Yang; Hyun Ho Kim; Byoung Yong Shim; Stephen Ahn
Journal:  Curr Oncol       Date:  2022-09-08       Impact factor: 3.109

3.  Bone Mineral Density as an Individual Prognostic Biomarker in Patients with Surgically-Treated Brain Metastasis from Lung Cancer (NSCLC).

Authors:  Inja Ilic; Anna-Laura Potthoff; Valeri Borger; Muriel Heimann; Daniel Paech; Frank Anton Giordano; Leonard Christopher Schmeel; Alexander Radbruch; Patrick Schuss; Niklas Schäfer; Ulrich Herrlinger; Hartmut Vatter; Asadeh Lakghomi; Matthias Schneider
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

Review 4.  Temporal Muscle and Stroke-A Narrative Review on Current Meaning and Clinical Applications of Temporal Muscle Thickness, Area, and Volume.

Authors:  Masahito Katsuki; Yukinari Kakizawa; Akihiro Nishikawa; Yasunaga Yamamoto; Toshiya Uchiyama; Masahiro Agata; Naomichi Wada; Shin Kawamura; Akihito Koh
Journal:  Nutrients       Date:  2022-02-06       Impact factor: 5.717

5.  Benchmarking Safety Indicators of Surgical Treatment of Brain Metastases Combined with Intraoperative Radiotherapy: Results of Prospective Observational Study with Comparative Matched-Pair Analysis.

Authors:  Motaz Hamed; Anna-Laura Potthoff; Julian P Layer; David Koch; Valeri Borger; Muriel Heimann; Davide Scafa; Gustavo R Sarria; Jasmin A Holz; Frederic Carsten Schmeel; Alexander Radbruch; Erdem Güresir; Niklas Schäfer; Patrick Schuss; Stephan Garbe; Frank A Giordano; Ulrich Herrlinger; Hartmut Vatter; Leonard Christopher Schmeel; Matthias Schneider
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.